1 Poster Session 1

Complementary Techniques for Challenging Radiolabeled In Vivo/in Vitro Metabolism Studies: Advantage and Limitation
Heasook Kim-Kang, Q2 Solutions, a Quintiles Quest Joint Venture; Jessica Shoutz, Q2 Solutions; Richard Smith, Q2 Solutions; Shelby Anderson, Q2 Solutions
Development of a quantitative bioanalytical method for the assessment of adenosine in pre-clinical and clinical tumor samples.
Kelly J Goodwin, AstraZeneca; Alexandra Borodovsky, AstraZeneca; Richard Woessner, AstraZeneca; Eric Gangl, AstraZeneca; Ujjal Sarkar, AstraZeneca; Petar Pop-Damkov, AstraZeneca; Natalie Jones, AstraZeneca; Adrian Fretland, AstraZeneca
The Use of Desorption Electrospray Ionisation (DESI) Mass Spectrometry Imaging (MSI) for Direct Drug Analysis in Polymeric Implants
Elizabeth E Pierson, Merck Research Laboratories; William P Forrest, Merck Research Laboratories; Megan Mackey, Merck Research Laboratories; Roy Helmy, Merck Research Laboratories; Hernando J Olivos, Waters Corporation; Anthony J Midey, Waters Corporation; Michael A Batey, Waters Corporation; Bindesh Shrestha, Waters Corporation
OPTIMIZATION OF DEFINITIVE PPB USING THE RED DEVICE FOR A HIGH BINDING COMPOUND AT A LOW CONCENTRATION
Wei Sun, Sanofi; Stacy Ho, Sanofi; Walter Korfmacher, Sanofi; Thomas O'Shea, Sanofi
HRMS Data Acquisition Coupled with Advanced Data Processing for Confident Metabolite Profiling
Kelly Wang, Gilead Sciences, Inc.; Kate Comstock, Thermofisher Scientific; Caroline Ding, Thermo Fisher Scientific
Ultra High Resolution MS for Confident Metabolite Structure Identification
Kate Comstock, Thermofisher Scientific; Seema Sharma, Thermofisher Scientific; Caroline Ding, Thermo Fisher Scientific
Measuring plasma protein binding of Liraglutide using the EScalate Assay
Hinnerk Boriss, Sovicell gmbH; Jan Ungewiss, 3B Pharmaceuticals
DEVELOPMENT OF MALDI MSI METHODS FOR DETECTION, IDENTIFICATION AND LOCALIZATION OF TENOFOVIR AND TENOFOVIR DIPHOSPHATE
Herana Kamal Seneviratne, Department of Medicine - Division of Clinical Pharmacology, The Johns Hopkins University, School of Medicine; Namandjé N. Bumpus, Department of Medicine - Division of Clinical Pharmacology, The Johns Hopkins University, School of Medicine
Rapid and Versatile MS-based immunoassays for Targeted Cytochrome P450 and Transporter Profiling in Tissue and Cell Culture Lysates
Frederik Weiss, SIGNATOPE GmbH; Helen Hammer, SIGNATOPE GmbH; Felix Schmidt, NMI Natural and Medical Sciences Institute at the University of Tuebingen; Hannes Planatscher, SIGNATOPE GmbH; Cornelia Sommersdorf, SIGNATOPE GmbH; Thomas O. Joos, SIGNATOPE GmbH; Oliver Poetz, SIGNATOPE GmbH
USE OF GRAS OR DIETARY COMPOUNDS TO IMPROVE THE ORAL BIOAVAILABILITY OF BUPRENORPHINE
Neha V Maharao, Virginia Commonwealth University; Phillip M Gerk, Virginia Commonwealth Univ
SEMI-MECHANISTIC MODELLING APPROACH TO ESTIMATE RIFAMPICIN IN VIVO OATP KI USING BIOMARKER COPROPORPHYRIN 1 AND ROSUVASTATIN AS PROBES
Shelby Barnett, Centre for Applied Pharmacokinetic Research, University of Manchester; Kayode Ogungbenro, Centre for Applied Pharmacokinetic Research, University of Manchester; Karelle Menochet, Investigative ADME, UCB; Hong Shen, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company; W. Griffith Humphreys, Bristol-Myers Squibb Company; Aleksandra Galetin, Centre for Applied Pharmacokinetic Research, University of Manchester
Novel biomarker for detecting human-specific hepatocyte injury in humanized liver mouse model
Hiroshi Suemizu, Central Institute for Experimental Animals; Nao Yoneda, Central Institute for Experimental Animals; Kenji Kawai, Central Institute for Experimental Animals; Megumi Nishiwaki, CLEA Japan, Inc.; Riichi Takahashi, Central Institute for Experimental Animals
Biomarker Monitoring by Quantitative MALDI Imaging: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology
Rima AIT-Belkacem, ImaBiotech; Vanesa Bol, iTeos Therapeutics SA; Bruno Gomes, iTeos Therapeutics SA; Gregory Hamm, Imabiotech; Stefan Linehan, ImaBiotech Corp; Jonathan Stauber, Imabiotech
PREDICTION OF BICTEGRAVIR HUMAN PHARMACOKINETICS FROM PROTEIN BINDING AND IN VITRO-IN VIVO CORRELATION
Jianhong Wang, Gilead Sciences, Inc.; Scott Lazerwith, Medicinal Chemistry, Gilead Sciences, Inc.; Haolun Jin, Medicinal Chemistry, Gilead Sciences, Inc.; Philip Morganelli, Medicinal Chemistry, Gilead Sciences, Inc.; Peter Pyun, Medicinal Chemistry, Gilead Sciences, Inc.; Jennifer Tang, Drug Metabolism, Gilead Sciences, Inc.; Mike Matles, Drug Metabolism, Gilead Sciences, Inc.; Judy Mwangi, Drug Metabolism, Gilead Sciences, Inc.; Kelly Wang, Gilead Sciences, Inc.; Gene Eisenberg, Drug Metabolism, Gilead Sciences, Inc.; Bernard P. Murray, Gilead Sciences, Inc.; Gerry Rhodes, Drug Metabolism, Gilead Sciences, Inc.; Heather Zhang, Clinical Pharmacology, Gilead Sciences, Inc.; Joseph Custodio, Clinical Pharmacology, Gilead Sciences, Inc.
APPLICATION OF A LOW INTRINSIC CLEARANCE ASSAY IN PRECLINICAL DRUG DISCOVERY.
Beth Williamson, Evotec; Paul Lancett, Evotec; Mathias Lorbeer, Evotec; Robert Riley, Evotec; Patrick Barton, Evotec
enantioselective glucuronidation of lorazepam by ugt2b7 and ugt2b15: assignment of fractional metabolism and IMPACT of ugt2b15 genotype on lorazepam pharmacokinetics
Jian Lin, Pfizer Worldwide Research & Development; Mark Niosi, Pfizer Inc.; Kimberly Lapham, Pfizer, Inc.; Susanna Tse, Pfizer Inc.; Theunis C. Goosen, Pfizer Inc., Medicinal Sciences
SUCCESSFUL PREDICTION OF IN VIVO HEPATOBILIARY CLEARANCE AND HEPATIC CONCENTRATIONS OF ROSUVASTATIN USING SANDWICH-CULTURED RAT HEPATOCYTES, TRANSPORTER-EXPRESSING CELL LINES, AND QUANTITATIVE PROTEOMICS
Kazuya Ishida, University of Washington; Mohammed Ullah, F. Hoffmann-La Roche Ltd; Beáta Tóth, SOLVO Biotechnology; Viktória Juhász, SOLVO Biotechnology; Jashvant D. Unadkat, University of Washington
WHEN DOES THE RATE-DETERMINING STEP IN HEPATIC CLEARANCE OF A DRUG SWITCH FROM SINUSOIDAL UPTAKE CLEARANCE TO ALL HEPATOBILIARY CLEARANCES?
Gabriela Patilea-Vrana, University of Washington; Jashvant D. Unadkat, University of Washington
ENHANCED CELLULAR CLERANCE OF GOLD NANOPARTICULES BY COPPER CONGUGATIONS IN MOUSE PRIMARY HEPATOCYTES AND KUPFFER CELLS
Xiaodong Wang, University of Rhode Island; YiTzai Chen, University of Rhode Island; Bingfang Yan, University of Rhode Island
NOVEL N-METHYLATION OF BI 187004 BY THIOL S-METHYLTRANSFERASE
Hlaing H Maw, Boehringer-Ingelheim Pharmaceuticals, Inc.; Aaron Teitelbaum, Boehringer Ingelheim
Characterization of Phase I and Phase II metabolism of UR-1102, a novel agent for the treatment of gout
Mizuki Yamane, Chugai pharmaceutical Co., Ltd.; Toshito Nakagawa, Chugai pharmaceutical Co., Ltd.; Masaki Ishigai, Chugai pharmaceutical Co., Ltd.
GLUCURONIDATION AND SULFONATION OF HYDROXYLATED TETRABROMODIPHENYL ETHERS
Katherine Viviana Cisneros, University of Florida; Vinayak Agarwal, Georgia Institute of Technology; Margaret O James, University of Florida
INDUSTRY STANDARD UGT1A3 PROBE SUBSTRATE CDCA: A SECOND LOOK
Jonathan J. Novak, Pfizer, Inc.; Jian Lin, Pfizer, Inc.; Keith Riccardi, Pfizer, Inc.; Theunis C. Goosen, Pfizer Inc.; Kimberly Lapham, Pfizer, Inc.
The Impact of AK2 Genetic Variants on the Phosphorylation of the Anti-HIV Drug, Tenofovir
Joseph Tillotson, The Johns Hopkins University, School of Medicine; Namandje N. Bumpus, The Johns Hopkins University, School of Medicine
Induction of Human Cytochrome P450 3A Enzymes in Hepatic and Placental Cells by Thalidomide and Relevance to Bioactivation
Hiroshi Yamazaki, Showa Pharmaceutical Univ; Norie Murayama, Showa Pharmaceutical Univ; Makiko Shimizu, Showa Pharmaceutical Univ; F. Peter Guengerich, Vanderbilt University School of Medicine
THE IMPACT OF A CYP2C8-CYP3A4 PROTEIN-PROTEIN INTERACTION ON TIME DEPENDENT INHIBITION OF CYP2C8.
Andrea Whitcher-Johnstone, Boehringer Ingelheim Pharmaceuticals Inc; Tom S. Chan, Boehringer Ingelheim Pharmaceuticals Inc.
HEPATIC LIPID ACCUMULATION IN EXPERIMENTAL HEPARG MODEL FOR STEATOSIS INFLUENCES BUPROPION BIOTRANSFORMATION
Anitha Saravanakumar, University of Rhode Island; Enoch Cobbina, University of Rhode Island; Xin Bush, University of Rhode Island; Fatemeh Akhlaghi, University of Rhode Island
Biochemical and kinetic characterization of CYP26C1 in retinoic acid and 4-oxo-all-trans-retinoic acid metabolism
Guo Zhong, Department of Pharmaceutics, University of Washington; David Ortiz, Department of Medicinal Chemistry, University of Washington; Jay Kirkwood, Department of Pharmaceutics, University of Washington; Alex Zelter, Department of Biochemistry, University of Washington; Abhinav Nath, University of Washington; Nina Isoherranen, Department of Pharmaceutics, University of Washington
Allelic Variants of CYP2D6 have Altered Drug Metabolite Profile, Kinetics, and Susceptibility to Mechanism-based Inactivation
Laura Lowe Furge, Kalamazoo College; Sarah M. Glass, Kalamazoo College; Christi Cho, Kalamazoo College; Cydney M. Martell, Kalamazoo College; Jacqueline M. Mills, Kalamazoo College; Alexandria K. Oswalt, Kalamazoo College; Sabrina Leddy, Kalamazoo College
Solving substrate interactions of CYP1A2 with non-PAH substrates on the template system: Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions.
Yasushi Yamazoe, Food Safety Commission, Cabinet Office, Government of Japan; Kouichi Yoshinari, School of Pharmaceutical Sciences, University of Shizuoka
The role of transcription factor HNF1α and long non-coding RNA HNF1α-AS1 in the regulation of cytochrome P450s and nuclear receptors in liver cells
Liming Chen, University of Connecticut School of Pharmacy; Yifan Bao, University of Connecticut School of Pharmacy; Stephanie Piekos, University of Connecticut School of Pharmacy; Xiao-bo Zhong, University of Connecticut School of Pharmacy
HUMAN METABOLITES OF BOSENTAN PRODUCED BY ENZYMES IN HYPHA’S POLYCYPSTM CYTOCHROME P450 KIT.
Jonathan Steele, Hypha Discovery Ltd; Antonio de Riso, Hypha Discovery Ltd; Headley Williams, Hypha Discovery Ltd; Richard Phipps, Hypha Discovery Ltd; Silvia Bardoni, Hypha Discovery Ltd; Chris Drake, Hypha Discovery Ltd; Stephen Wrigley, Hypha Discovery Ltd; Julia Shanu-Wilson, Hypha Discovery Ltd; Frank Scheffler, Hypha Discovery Ltd; Sebastian Schulz, University College London; John Ward, University College London
CRYSTAL STRUCTURE OF CYP2B6 IN COMPLEX WITH AN EFAVIRENZ ANALOG: FROM PLASTICITY TO PI INTERACTIONS IN CYP2B ENZYMES.
Manish B Shah, Albany College of Pharmacy and Health Sciences; James R Halpert, University of Connecticut
DESIGN AND DEVELOPMENT OF METABOLICALLY COMPETENT CELL LINES FOR HIGH THROUGHPUT, CHEMICAL COMPOUND, TOXICITY TESTING
Gene Pegg, MilliporeSigma; Maureen Bourner, MilliporeSigma; Vi Chu, MilliporeSigma; Naohisa Yoshioka, MilliporeSigma; Mark Angeles, MilliporeSigma; Yongling Xiao, MilliporeSigma; David Thompson, MilliporeSigma
Dependence of the rhCYP3A4 intersystem extrapolation factor on CYP3A substrate
Alyssa L. Dantonio, Pfizer Inc., Medicinal Sciences; Angela C Doran, Pfizer Inc., Medicinal Sciences; R. Scott Obach, Pfizer Inc.
Time dependent inhibition of P450 by phenelzine in human liver microsomes
Mandy Xu, Pharmaron; Yu Wang, Pharmaron; Cui Yuan, Pharmaron; Danxi Li, Pharmaron; Stephen Harris, Pharmaron UK Ltd
EVALUATION OF METHOXSALEN AS A PAN-CYP450 DIRECT AND TIME DEPENDENT INHIBITOR IN HUMAN LIVER MICROSOMES: COMPARISON WITH ABT AS A TOOL FOR IN VITRO PHENOTYPING STUDIES
Raghava Choudary Palacharla, Suven Life Sciences Ltd; Parusharamulu Molgara, Suven Life Sciences Ltd.; Arun Kumar Manoharan, Suven Life Sciences Ltd; Ilayaraja Kalaikadhiban, Suven Life Sciences Ltd.; Ranjith kumar Ponnamaneni, Suven Life Sciences Ltd; Gopinadh Bhyrapuneni, Suven Life Sciences Ltd; Ramakrishna Nirogi, Suven Life Sciences Ltd
ROLE OF P450 ENZYMES IN CIGARETTE SMOKE INDUCED LUNG INFLAMMATION
Matthew Hartog, SUNY Polytechnic Institute; Xinxin Ding, SUNY Polytechnic Institute
CYP2C11 gene knockout does not change blood pressure levels of rats fed on a normal or a high-salt lab diet.
Yuan Wei, Jiangsu University; Li Yang, Jiangsu University; Danjuan Sui, Jiangsu University; Xiaoyan Zhang, Jiangsu University; Dujun Wang, Jiangsu University; Changsuo Wang, Jiangsu University
Humanized, Transgenic Worms to Study the Role of Mitochondrial CYP2E1 in Toxicant-Induced Mitochondrial Dysfunction and Neurodegeneration
Jessica Helene Hartman, Duke University; Kacy L Gordon, Duke University; David R Sherwood, Duke University; Joel N Meyer, Duke University
Development of a multitask deep learning QSAR model using data from individual Cytochrome P450 isozymes.
Pranav Shah, NIH; Alexey Zakharov, NIH; R. Scott Obach, Pfizer Inc.; Anton Simeonov, NIH; Cornelis Hop, Genentec, Inc; Dac-Trung Nguyen, NIH; Eric Gonzalez, NIH; Hongmao Sun, NIH; Xin Xu, NIH
CONTRIBUTION OF CYTOCHROME P450 AND OTHER ENZYMES TO THE METABOLISM OF FDA APPROVED DRUGS BETWEEN 2005-2016
Anitha Saravanakumar*, University of Rhode Island; Armin Sadighi; Rachel Ryu, University of Rhode Island; Fatemeh Akhlaghi, University of Rhode Island
Development of a Physiologically-based Pharmacokinetic Model to Understand the Nonlinear Pharmacokinetics of Letermovir and Exposure Differences between Populations
Dapeng Chen, Merck Research Laboratories, Pharmacokinetics, Pharmacodynamics, and Drug Metabolism; Georgy Hartmann, Merck Research Laboratories, Pharmacokinetics, Pharmacodynamics, and Drug Metabolism; Karsten Menzel, Merck Research Laboratories, Pharmacokinetics, Pharmacodynamics, and Drug Metabolism; Carolyn Cho, Merck Research Laboratories, Pharmacokinetics, Pharmacodynamics, and Drug Metabolism
Rat Phenotypic Evaluation of Several Human Cytochrome P450 3A4 Substrates
Jenny Wen, Dart Neuroscience LLC; Jane Angeles, Dart Neuroscience LLC; Anne Danks, Dart Neuroscience LLC; Kathe Stauber, Dart Neuroscience LLC
T0901317-induced hepatic steatosis dramatically decreases CYP3A and CYP2C activities in mice
Jessica Virgili, Université Laval; Sylvie Pilote, CRIUCPQ; Camille Thibault, Université Laval; Éric Jubinville, CRIUCPQ; Joanie Routhier, Université Laval; Benoît Drolet, Université Laval; Mathieu C. Morissette, Université Laval; Chantale Simard, Université Laval
Is cigarette smoking exacerbating the effect of non-alcoholic fatty liver disease (NAFLD) on CYP3A- and CYP2C-mediated drug metabolism?
Jessica Virgili, Université Laval; Sylvie Pilote, CRIUCPQ; Camille Thibault, Université Laval; Éric Jubinville, CRIUCPQ; Joanie Routhier, Université Laval; Benoît Drolet, Université Laval; Mathieu C. Morissette, Université Laval; Chantale Simard, Université Laval
ROLE OF FLAVIN-CONTAINING MONOOXYGENASES IN THE SPECIES-DEPENDENT METABOLISM OF AN IRREVERSIBLE THIOURACIL-BASED INACTIVATOR OF HUMAN MYELOPEROXIDASE
Heather Eng, Pfizer Global Research and Development; Raman Sharma, Pfizer Worldwide Research and Development; Angela Wolford, Pfizer Inc.; Li Di, Pfizer Inc.; Amit S. S Kalgutkar, Pfizer Worldwide Research and Development
CHANGES IN NICOTINE METABOLIC PATHWAYS ACROSS PREGNANCY: A LONGITUDINAL STUDY
Taraneh Taghavi, University of Toronto; Christopher A. Arger, University of Vermont; Sarah H. Heil, University of Vermont; Stephen T. Higgins, University of Vermont; Rachel F. Tyndale, University of Toronto
DECREASED CYP3A4 ACTIVITY AND PROTEIN IN NONALCOHOLIC FATTY LIVER (NAFL) AND NONALCOHOLIC STEATOHEPATITIS (NASH)
Rohitash Jamwal, University of Rhode Island; Benjamin J Barlock, University of Rhode Island; Sravani Adusumalli, University of Rhode Island; Ken Ogasawara, University of Rhode Island; Suzanne M De La Monte, Warren Alpert Medical School of Brown University; Fatemeh Akhlaghi, University of Rhode Island
Expression of four porcine CYPs in E. coli and development of fluorogenic CYP inhibition assays.
Michael W. Voice, Cypex Ltd.; Gillian M. Macintyre, Cypex Ltd.; Michael P. Pritchard, Cypex Ltd.
Species and Cell-Type Independence in Fraction Unbound of Liver Tissues, Primary Hepatocytes and Cell-lines
Keith Riccardi, Pfizer, Inc.; Sangwoo Ryu, Pfizer Inc.; Dhirender Singh, Navinta LLC; Phil Yates, Pfizer; Brian Holder, Pfizer; Brendon Kapinos, Pfizer; Jian Lin, Pfizer, Inc.; George Chang, Pfizer; Li Di, Pfizer Inc.
Nonclinical Characterization of the Pharmacokinetics and Disposition of Inotuzumab Ozogamicin, a Calicheamicin-Containing Antibody-Drug Conjugate
Theodore R. Johnson, Pfizer Inc.; Andrew J. Bessire, Pfizer, Inc.; Michelle Gleave, Unilabs York Bioanalytical Solutions; Angus N.R. Nedderman, Unilabs York Bioanalytical Solutions; Mania Kavosi, Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc.; T. Eric Ballard, Pfizer, Inc.
POLYCYSTIC KIDNEY DISEASE ALTERS THE HEPATOBILIARY DISPOSITION OF TOLVAPTAN AND METABOLITES
James J. Beaudoin, The University of North Carolina at Chapel Hill; Jacqueline Bezençon, The University of North Carolina at Chapel Hill; Yanguang Cao, The University of North Carolina at Chapel Hill; Sharin Roth, Otsuka Pharmaceutical Development & Commercialization, Inc.; William Brock, Brock Scientific Consulting, LLC; Katsuhiko Mizuno, Otsuka Pharmaceutical Co., Ltd.; Kim L.R. Brouwer, The University of North Carolina at Chapel Hill
Feasibility of Establishing a Veterinary Marker to Total Residue In Edible Tissues Using High Resolution Mass Spectrometry
Wei Tong, Boehringer Ingelheim Animal Health; Hong Zuo, Boehringer Ingelheim Animal Health; Cyrus Zarabadipour, Boehringer Ingelheim Animal Health; Amanda Mullins, Boehringer Ingelheim Animal Health; Dietmar Hamel, Boehringer Ingelheim Animal Health; Rose Huang, Boehringer Ingelheim Animal Health; Laura Letendre, Boehringer Ingelheim Animal Health
Design of colon specific delivery system for mice by visualizing the gastrointestinal localization using in vivo imaging technology.
Masaru Iwasaki, Daiichi Sankyo RD Novare Co., Ltd.; Wakaba Matsumoto, Daiichi Sankyo RD Novare Co., Ltd.; Mayumi Kanda, Daiichi Sankyo RD Novare Co., Ltd.; Norio Suzuki, Daiichi Sankyo Co., Ltd.; Yuki Kawabata, Daiichi Sankyo Co., Ltd.; Rira Watanabe, Daiichi Sankyo Co., Ltd.; Yoshiyuki Yabe, Daiichi Sankyo Co., Ltd.; Hideo Kobayashi, Daiichi Sankyo RD Novare Co., Ltd.; Masayuki Takahashi, Daiichi Sankyo RD Novare Co., Ltd.
MALDI MASS SPECTROMETRY IMAGING FOR DETERMINATION OF THE EFFECTS OF DOSING PARAMETERS ON THE PENETRATION OF AN ANTIFUNGAL AFTER TOPICAL DOSING
Erin Seeley, Protea Biosciences; Stephen Rumbelow, Croda Inc.; Callee Walsh, Protea Biosciences
New strategy for risk assessment of reactive metabolites based on Body Burden
Nobuyuki Kakutani, Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, JAPAN TOBACCO INC.; Mai Shimizu, Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, JAPAN TOBACCO INC.; Toyomichi Nanayama, Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, JAPAN TOBACCO INC.; Yukihiro Nomura, Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, JAPAN TOBACCO INC.; Mitsuru Takahashi, Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, JAPAN TOBACCO INC.; Motohiro Kogayu, Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, JAPAN TOBACCO INC.
Establishment of Novel Culture Method for Maintaining Stemness of Human iPS Cell-Derived Intestinal Stem Cells
Satoshi Kondo, Department of Drug Safety Research, Nonclinical Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd.; Shota Mizuno, Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University; Yue Yu, Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University; Wakana Matsumura, Educational Research center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University; Takahiro Iwao, Educational Research center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University; Tamihide Matsunaga, Educational Research center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University
ACCELERATOR MASS SPECTROMETRY –EMERGING USES IN THE ANALYSIS OF BIOTHERAPEUTICS WITH A SENSITIVITY IN FEMTOGRAM RANGE
Mitesh Sanghvi, Xceleron Inc., A Pharmaron Company; Stephen L. English, Xceleron Inc., A Pharmaron Company; Ricardo Diaz, Xceleron Inc., A Pharmaron Company; Eric Guarin, Xceleron Inc., A Pharmaron Company; Marie Croft, Xceleron Inc., A Pharmaron Company
Early human in vivo pharmacokinetic predictions in drug discovery
Marie Ahlqvist, AstraZeneca IMED Biotech Unit; Bo Lindmark, AstraZeneca IMED Biotech Unit; Martin A. Hayes, AstraZeneca IMED Biotech Unit; Ulrik Jurva, AstraZeneca IMED Biotech Unit; Marcus Olivecrona, AstraZeneca IMED Biotech Unit; Eva Lundborg, AstraZeneca IMED Biotech Unit; Carola Wassvik, AstraZeneca IMED Biotech Unit; Rasmus Jansson Löfmark, AstraZeneca IMED Biotech Unit; Shalini Andersson, AstraZeneca IMED Biotech Unit
Desorption Electrospray Ionisation Mass Spectrometry Imaging of xenobiotic drugs and metabolites using Q-Tof and tandem quadrupole mass spectrometers for pharmaceutical development
Philippa J Hart, Waters Corporation; Emmanuelle Claude, Waters Corporation; Mark W Towers, Waters Corporation; Michael A Batey, Waters Corporation; Emrys Jones, Waters Corporation; Hernando J Olivos, Waters Corporation; Anthony J Midey, Waters Corporation
Evaluation of a dual parameter mitochondria toxicity assay in primary human hepatocytes
Weixi Kong, Icagen; Peter Deply, Icagen; Lilly Xu, Icagen
Evolving understanding of ADME PROPERTIES of oligonucleotide THERAPEUTICS
Helen L Shen, QPS, LLC; Armand G Ngounou-Wetie, QPS; Lakshmi Ramanathan, QPS; Wenbin Liu, QPS; Deborah Watson, QPS; Ron Laethem, QPS; Cornelia Smith, QPS
DEVELOPMENT OF MEDICAL COUNTERMEASURE PRODUCTS IN AUSTRALIA: COULD PHARMACOMETRICS ADDRESS CAPABILITY AND CAPACITY GAPS?
Thomas M. Polasek, Flinders University, Department of Clinical Pharmacology; Felicia Pradera, Defence Science and Technology Group, Department of Defence; Shane Seabrook, 4Commonwealth Science and Industrial Research Organisation; Kashyap Patel, d3 Medicine, A Certara Company; Emily J Woodward, Synchrogenix, A Certara Company; Craig R Rayner, Monash University, Monash Institute of Pharmaceutical Sciences
EFFECT OF BRUSATOL ESTER SIDE-CHAINS ON ITS CHEMOSENSITIZING AND CYTOTOXIC ACTIVITIES: A COUPLED ISSUE OF DRUGGABILITY WITH DRUG METABOLISM
YiTzai Chen, University of Rhode Island; Xiaodong Wang, University of Rhode Island; Bingfang Yan, University of Rhode Island
Characterization of the major metabolites found after plasma metabolite profiling of a BTK Inhibitor, BMS-986142, in FIH studies
Weiping Zhao, Bristol-Myers Squibb Research&Development; Wenying Li, Bristol-Myers Squibb; Ang Liu, Bristol Myers Squibb; Jianqing Li, Bristol Myers Squibb; Jun Dai, Bristol Myers Squibb; Janet Caceres-Cortes, Bristol-Myers Squibb; Sarah Traeger, Bristol Myers Squibb; James Burke, Bristol Myers Squibb; Lisa Christopher, Bristol-Myers Squibb; William Humphreys, Pharmaceutical Research Institute, Bristol-Myers Squibb Company; Mingshe Zhu, Bristol-Myers Squibb Research&Development
Membrane‐free culture and real‐time barrier integrity assessment of perfused intestinal epithelium tubes
Bas Trietsch, Mimetas; Elena Naumovska, Mimetas; Dorota Kurek, Mimetas; Anthony D Saleh, Mimetas; Henriëtte Lanz, Mimetas; Jos Joore, Mimetas; Stefan Kustermann, Roche; Adrian Roth, Roche; Annie Moisan, Roche; Paul Vulto, Mimetas
See more of: General Abstracts